Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy.
Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
J Hepatol. 2017 Nov;67(5):950-956. doi: 10.1016/j.jhep.2017.07.002. Epub 2017 Jul 14.
BACKGROUND & AIMS: Patients with cirrhosis display enhanced blood levels of factor VIII, which may result in harmful activation of the clotting system; however, the underlying mechanism is unknown.
We performed a cross-sectional study in patients with cirrhosis (n=61) and matched controls (n=61) comparing blood levels of factor VIII, von Willebrand factor (vWf), lipopolysaccharide (LPS) and positivity for Escherichia coli DNA. Furthermore, we performed an in vitro study to investigate if LPS, in a concentration range similar to that found in the peripheral circulation of cirrhotic patients, was able to elicit factor VIII secretion from human umbilical vein endothelial cells (HUVEC).
Patients with cirrhosis displayed higher serum levels of LPS (55.8 [42.2-79.9] vs. 23.0 [7.0-34.0]pg/ml, p<0.001), factor VIII (172.0 [130.0-278.0] vs. 39.0 [26.0-47.0]U/dl, p<0.0001), vWf (265.0 [185.0-366.0] vs. 57.0 [48.0-65.0]U/dl, p<0.001) and positivity for Escherichia coli DNA (88% vs. 3%, p<0.001, n=34) compared to controls. Serum LPS correlated significantly with factor VIII (r=0.80, p<0.001) and vWf (r=0.63, p<0.001). Only LPS (beta-coefficient=0.70, p<0.0001) independently predicted factor VIII levels. The in vitro study showed that LPS provoked factor VIII and vWf release from HUVEC via formation and secretion of Weibel-Palade bodies, a phenomenon blunted by pre-treating HUVEC with an inhibitor of Toll-like receptor 4.
The study provides the first evidence that LPS derived from gut microbiota increases the systemic levels of factor VIII via stimulating its release by endothelial cells. Lay summary: Cirrhosis is associated with thrombosis in portal and systemic circulation. Enhanced levels of factor VIII have been suggested to play a role but the underlying mechanism is still unclear. Here we show that patients with cirrhosis display a concomitant increase of factor VIII and lipopolysaccharide (LPS) from Escherichia coli and suggest that LPS contributes to the release of factor VIII from endothelial cells.
肝硬化患者血液中因子 VIII 水平升高,可能导致凝血系统的有害激活;然而,其潜在机制尚不清楚。
我们对 61 例肝硬化患者和 61 例匹配对照进行了一项横断面研究,比较了因子 VIII、血管性血友病因子 (vWf)、脂多糖 (LPS) 和大肠埃希氏菌 DNA 阳性率。此外,我们进行了一项体外研究,以调查 LPS 是否能从人脐静脉内皮细胞 (HUVEC) 中引发因子 VIII 的分泌,其浓度范围类似于肝硬化患者外周循环中的浓度。
肝硬化患者血清 LPS 水平较高(55.8[42.2-79.9]比 23.0[7.0-34.0]pg/ml,p<0.001),因子 VIII(172.0[130.0-278.0]比 39.0[26.0-47.0]U/dl,p<0.0001),vWf(265.0[185.0-366.0]比 57.0[48.0-65.0]U/dl,p<0.001)和大肠埃希氏菌 DNA 阳性率(88%比 3%,p<0.001,n=34)高于对照组。血清 LPS 与因子 VIII(r=0.80,p<0.001)和 vWf(r=0.63,p<0.001)呈显著正相关。只有 LPS(β系数=0.70,p<0.0001)独立预测因子 VIII 水平。体外研究表明,LPS 通过形成和分泌 Weibel-Palade 小体刺激 HUVEC 释放因子 VIII 和 vWf,该现象可通过用 Toll 样受体 4 抑制剂预处理 HUVEC 而减弱。
该研究首次提供了证据表明,来自肠道微生物群的 LPS 通过刺激内皮细胞释放因子 VIII 来增加全身性因子 VIII 水平。
非专业人士请不要随意修改译文内容,以免造成误解。